Detalhe da pesquisa
1.
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
Br J Cancer
; 130(1): 73-81, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37951974
2.
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
Future Oncol
; 20(10): 563-578, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38126311
3.
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Lancet Oncol
; 22(11): 1541-1559, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34600602
4.
Radiographic progression-free survival in the ACIS trial for prostate cancer - Authors' reply.
Lancet Oncol
; 23(1): e5-e6, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34973233
5.
Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review.
Eur Urol Oncol
; 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38744587
6.
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.
Eur Urol Oncol
; 2023 Dec 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38072759
7.
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study.
Eur J Cancer
; 193: 113290, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708629
8.
Tracking the randomized rollout of a Veterans Affairs opioid risk management tool: A multi-method implementation evaluation using the Consolidated Framework for Implementation Research (CFIR).
Implement Res Pract
; 3: 26334895221114665, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-37091078
9.
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer.
Prostate Cancer
; 2022: 5454727, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36212187
10.
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
J Clin Oncol
; 39(20): 2294-2303, 2021 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33914595
11.
Tracking implementation strategies in the randomized rollout of a Veterans Affairs national opioid risk management initiative.
Implement Sci
; 15(1): 48, 2020 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32576214